Latest Market News

Somerset Minerals has pushed back the closing date for its non-renounceable entitlement offer, giving shareholders until 5 August 2026 to participate in the capital raise aimed at funding its copper exploration projects in Nunavut and Ecuador.

Samuel Holdings has agreed not to trade its shares in DGR Global without Takeovers Panel approval, locking in its stake during ongoing proceedings sparked by Jeremy Raper's application.

Imperial Pacific Limited reported a robust 26.5% rise in net worth to $13.5 million for the year ending June 2026, driven by strong investment portfolio growth and a $221,000 capital raise.

Starpharma Holdings is raising approximately $32 million through a fully underwritten 1-for-7.5 renounceable entitlement offer priced at $0.57 per share, discounting the stock by 25%. Proceeds will fund the DEP HER2-Lu Phase 1 trial and expand its dendrimer-based oncology pipeline.

Excelsior Capital Limited plans a capital return of approximately A$27.43 million, about 94.6 cents per share, as it moves to wind up its investment portfolio and delist from the ASX. Shareholder approval is sought at a meeting on 17 August 2026, with trading suspension and removal from the official list scheduled for late August.

Resolution Minerals has earned FAST-41 transparency status for its Golden Gate Project in Idaho, marking its second such designation and positioning the company as a key player in U.S. critical minerals supply chain development.

London City Equities has boosted its net assets to a record $29 million for FY2026, driven by the sale of its Fiducian Group stake and the completion of Excelsior Capital’s liquidation.

Bass Oil reported a 3% production increase in June 2026, driven by Indonesian output and Cooper Basin gains. The Bunian 6 well drilling is underway, expected to double group production, while the Vanessa gas field acquisition opens new gas sales and commercialisation pathways.

Jade Gas Holdings (ASX: JGH) has voluntarily suspended its shares on the ASX ahead of an announcement expected by 20 July regarding a development partnership and funding commitment.

Dimerix has acquired DMX-652, a Phase 2-ready oral drug candidate targeting acute kidney injury, expanding its renal disease portfolio. The acquisition includes patent rights, an FDA-approved trial protocol, and funding to initiate clinical development.

MotorCycle Holdings has uncovered leave loading underpayments affecting current employees since 2020, with remediation costs estimated up to $1.3 million. The company is voluntarily engaging the Fair Work Ombudsman while conducting a complex review of historical payroll compliance.

LTR Pharma has formalised its US commercialisation strategy by signing a definitive agreement with telehealth leader Shed, targeting at least 150,000 ROXUS units in the first year through digital men’s health platforms.